Risk of venous and arterial thromboembolic events in patients with metastatic breast cancer treated with bevacizumab: A meta-analysis

被引：0
|
作者：
Calvo, V.
Ramirez, N.
Saura, C.
Vidal, M.
Velasco, A.
Llombart-Cussac, A.
Cortes-Funes, H.
Miles, D.
Baselga, J.
Cortes, J.
机构：
[1] Hosp Univ Princesa, Madrid, Spain
[2] Fdn Jimenez Diaz, E-28040 Madrid, Spain
[3] Hosp Valle De Hebron, Barcelona, Spain
[4] Hosp Arnau Vilanova, Lleida, Spain
[5] Hosp Univ 12 Octubre, Med Oncol Serv, Madrid, Spain
[6] Mt Vernon Canc Ctr, Northwood, Middx, England
[7] Vall dHebron Univ Hosp, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1043
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1043
引用
收藏
页数：1
相关论文
共 50 条
  • [1] INCREASED RISK OF CARDIAC ISCHEMIA AND ARTERIAL THROMBOEMBOLIC EVENTS IN CANCER PATIENTS TREATED WITH BEVACIZUMAB: A META-ANALYSIS
    Ranpura, Vishal
    Chuang, Jeff
    Wu, Shenhong
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2010, 55 (10)
  • [2] Risk of venous and arterial thromboembolic events in cancer patients treated with gemcitabine: a systematic review and meta-analysis
    Qi, Wei-Xiang
    Lin, Feng
    Sun, Yuan-Jue
    Tang, Li-Na
    Shen, Zan
    Yao, Yang
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 76 (03) : 338 - 347
  • [3] Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab
    Scappaticci, Frank A.
    Skillings, Jamey R.
    Holden, Scott N.
    Gerber, Hans-Peter
    Miller, Kathy
    Kabbinavar, Fairooz
    Bergsland, Emily
    Ngai, James
    Holmgren, Eric
    Wang, Jiuzhou
    Hurwitz, Herbert
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (16): : 1232 - 1239
  • [4] Risk of venous and arterial thromboembolic events in women with advanced breast cancer treated with CDK 4/6 inhibitors: A systematic review and meta-analysis
    Bolzacchini, Elena
    Pomero, Fulvio
    Fazio, Martina
    Civitelli, Chiara
    Fabro, Giulia
    Pellegrino, Domenico
    Giordano, Monica
    Squizzato, Alessandro
    THROMBOSIS RESEARCH, 2021, 208 : 190 - 197
  • [5] Risk of Serious Neutropenic Events in Cancer Patients Treated with Bevacizumab: A Meta-analysis
    Zhou, Fan
    Shao, Jiang-Hua
    Wu, Lin-Quan
    Yin, Xiang-Bao
    Yu, Xin
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (04) : 2453 - 2459
  • [6] Increased Risk of Cerebrovascular Events in Patients with Cancer Treated with Bevacizumab: A Meta-Analysis
    Zuo, Pei-Yuan
    Chen, Xing-Lin
    Liu, Yu-Wei
    Xiao, Chang-Liang
    Liu, Cheng-Yun
    PLOS ONE, 2014, 9 (07):
  • [7] Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
    Ranpura, Vishal
    Hapani, Sanjaykumar
    Chuang, Jeff
    Wu, Shenhong
    ACTA ONCOLOGICA, 2010, 49 (03) : 287 - 297
  • [8] Risk of Venous Thromboembolic Events in Patients With Cancer Treated With Aflibercept: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Kanukula, Raju
    Ganta, Shruthi
    Sirumalla, Yashaswee
    Salam, Abdul
    Baddam, Ravali
    Pasupuleti, Bhuvana C.
    AMERICAN JOURNAL OF THERAPEUTICS, 2019, 26 (04) : E549 - E552
  • [9] Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis
    Bo Liu
    Fengxia Ding
    Deying Zhang
    Guang-hui Wei
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 487 - 495
  • [10] Risk of venous and arterial thromboembolic events associated with VEGFR-TKIs: a meta-analysis
    Liu, Bo
    Ding, Fengxia
    Zhang, Deying
    Wei, Guang-hui
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (03) : 487 - 495
12345